WEBSITE BSE:0 NSE: Inc. Year: 1985 Industry: Pesticides & Agrochemicals My Bucket: Add Stock
Last updated: 14:41
No Notes Added Yet
Ambey Laboratories Limited, established in 1977 is a subsidiary of the ambey group which is a conglomerate with three divisions: FMCG, Crop Protection, and Natural Gums. Incorporated in Delhi, Ambey serves various industries across India, USA, Europe, and African countries. Ambey's FMCG division manufacturers home hygiene products under a popular brand name “TRISHULâ€. Natural Gums division focuses on producing and distributing Guar Gum which acts as a thickener, binder, and colloidal dispersion agent. Ambey Laboratories offers a div...Read More
Ambey Laboratories Limited, established in 1977 is a subsidiary of the ambey group which is a conglomerate with three divisions: FMCG, Crop Protection, and Natural Gums. Incorporated in Delhi, Ambey serves various industries across India, USA, Europe, and African countries. Ambey's FMCG division manufacturers home hygiene products under a popular brand name “TRISHULâ€. Natural Gums division focuses on producing and distributing Guar Gum which acts as a thickener, binder, and colloidal dispersion agent. Ambey Laboratories offers a diverse range of home hygine products catering to consumer needs in very commoditized market of India as well as some international markets too. At Ambey Group, focus is people and not just processes. They emphasize upon drawing the most qualified personnel and strike the balance by combining talent with a well conceived training schedule. We ensure that right kind of professionals are designated to complete the job, they are best qualified for. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹87 Cr.
Stock P/E 18.2
P/B 1.3
Current Price ₹34.9
Book Value ₹ 27.1
Face Value 10
52W High ₹48.3
Dividend Yield 0%
52W Low ₹ 16.2
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 82 | 85 | 105 | 120 | 131 | |
| Other Income | 1 | 1 | 3 | 2 | 2 | |
| Total Income | 82 | 85 | 108 | 122 | 133 | |
| Total Expenditure | 72 | 74 | 97 | 111 | 122 | |
| Operating Profit | 10 | 11 | 11 | 11 | 12 | |
| Interest | 4 | 3 | 2 | 2 | 3 | |
| Depreciation | 3 | 3 | 3 | 3 | 3 | |
| Exceptional Income / Expenses | 0 | 0 | -0 | -0 | 0 | |
| Profit Before Tax | 3 | 5 | 6 | 5 | 6 | |
| Provision for Tax | -7 | 1 | 0 | -2 | 1 | |
| Profit After Tax | 10 | 4 | 5 | 8 | 5 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 10 | 4 | 5 | 8 | 5 | |
| Adjusted Earnings Per Share | 21.1 | 2 | 3 | 4.1 | 1.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 9% | 16% | 0% | 0% |
| Operating Profit CAGR | 9% | 3% | 0% | 0% |
| PAT CAGR | -38% | 8% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -8% | NA% | NA% | NA% |
| ROE Average | 11% | 34% | 33% | 33% |
| ROCE Average | 11% | 19% | 22% | 22% |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Shareholder's Funds | -8 | 19 | 19 | 32 | 76 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 30 | 14 | 13 | 16 | 11 |
| Other Non-Current Liabilities | -6 | -5 | -0 | -2 | -1 |
| Total Current Liabilities | 22 | 22 | 22 | 31 | 40 |
| Total Liabilities | 37 | 50 | 54 | 77 | 126 |
| Fixed Assets | 16 | 25 | 25 | 24 | 23 |
| Other Non-Current Assets | 1 | 0 | 0 | 4 | 16 |
| Total Current Assets | 20 | 24 | 28 | 48 | 87 |
| Total Assets | 37 | 50 | 54 | 77 | 126 |
| #(Fig in Cr.) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 3 | 6 | 10 | -13 | -34 |
| Cash Flow from Investing Activities | -1 | -1 | -4 | -5 | -13 |
| Cash Flow from Financing Activities | -1 | -5 | -6 | 18 | 48 |
| Net Cash Inflow / Outflow | 0 | -0 | 0 | -0 | 0 |
| Closing Cash & Cash Equivalent | 1 | 0 | 0 | 0 | 1 |
| # | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 21.12 | 2.01 | 2.95 | 4.13 | 1.92 |
| CEPS(Rs) | 27.71 | 3.69 | 4.62 | 5.48 | 2.94 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -16.07 | 10.74 | 4.87 | 11.24 | 26.4 |
| Core EBITDA Margin(%) | 11.92 | 12.23 | 7.49 | 7.54 | 7.33 |
| EBIT Margin(%) | 8.81 | 9.33 | 7.24 | 6.52 | 6.85 |
| Pre Tax Margin(%) | 3.78 | 5.71 | 5.25 | 4.51 | 4.6 |
| PAT Margin (%) | 12.65 | 4.23 | 5 | 6.41 | 3.64 |
| Cash Profit Margin (%) | 16.59 | 7.74 | 7.83 | 8.5 | 5.58 |
| ROA(%) | 27.64 | 8.18 | 10.12 | 11.85 | 4.72 |
| ROE(%) | 0 | 63.82 | 37.82 | 52.08 | 11.01 |
| ROCE(%) | 28.72 | 25.38 | 25.37 | 21.4 | 11.43 |
| Receivable days | 31.11 | 33.42 | 21.05 | 33.71 | 82.19 |
| Inventory Days | 38.99 | 42.03 | 48.53 | 57.1 | 70.19 |
| Payable days | 89.08 | 82.3 | 62.59 | 53.06 | 33.43 |
| PER(x) | 0 | 0 | 0 | 0 | 20.97 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 1.52 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.46 | 0.42 | 0.3 | 0.4 | 1.06 |
| EV/Core EBITDA(x) | 3.58 | 3.27 | 2.96 | 4.49 | 12.08 |
| Net Sales Growth(%) | 0 | 3.5 | 23.9 | 14.93 | 8.96 |
| EBIT Growth(%) | 0 | 9.62 | -3.77 | 3.45 | 14.44 |
| PAT Growth(%) | 0 | -65.42 | 46.59 | 47.36 | -38.06 |
| EPS Growth(%) | 0 | -90.47 | 46.58 | 39.95 | -53.6 |
| Debt/Equity(x) | -4.19 | 0.95 | 1.63 | 1.41 | 0.62 |
| Current Ratio(x) | 0.92 | 1.13 | 1.29 | 1.56 | 2.19 |
| Quick Ratio(x) | 0.52 | 0.63 | 0.51 | 0.9 | 1.43 |
| Interest Cover(x) | 1.75 | 2.58 | 3.63 | 3.24 | 3.05 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0.41 |
| # | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 69.9 | 70.11 | 70.15 | 70.15 |
| FII | 1.46 | 0.01 | 0 | 0 |
| DII | 4.11 | 2.34 | 1.96 | 0.72 |
| Public | 24.53 | 27.54 | 27.89 | 29.13 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 1.74 | 1.75 | 1.75 | 1.75 |
| FII | 0.04 | 0 | 0 | 0 |
| DII | 0.1 | 0.06 | 0.05 | 0.02 |
| Public | 0.61 | 0.69 | 0.7 | 0.73 |
| Others | 0 | 0 | 0 | 0 |
| Total | 2.49 | 2.49 | 2.49 | 2.49 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
